Effectiveness of Combination Cisplatin-based Intravesical Chemotherapy for BGC-unresponsive Bladder Cancer

Helena Vila-Reyes*, G.Joel DeCastro, Izak Faiena, Jamie S. Pak, Kevin Lee, Gen Li, Christopher B. Anderson, Cory T. Abate-Shen, James M. McKiernan

Department of Urology at Columbia University Irving Medical Center and NewYork-Presbyterian Hospital

Abstract Number 20-8371
Cisplatin-based intravesical chemotherapy

- Up to 50% of high risk NMIBC patients relapse after BCG
- Intravesical salvage therapies response rates are <20%
- Retrospective review of patients who received 3-drug cisplatin based IV chemotherapy at our institution:
  1. CGC (Cabazitaxel + Gemcitabine + Cisplatin)
  2. DGC (Docetaxel + Gemcitabine + Cisplatin)
Cisplatin-based intravesical chemotherapy

- Total of 28 patients:
  - Highly pre-treated cohort (96% ≥2 BCG inductions, 43% other previous IV chemotherapies)
  - Initial complete response: 25 patients (89%)
  - No grade 3 or 4 adverse events or systemic toxicity
  - 16 patients (57%) had at least one decreased dose of Gem/Cis (per protocol or due to intolerance)

- At median follow-up time of 26 months (IQR 14-35):
  - Risk factors for recurrence:
    - Presence of CIS (HR 20.2)
    - Prostatic urethra involvement (HR 15.2)
    - Not receiving Gem/Cis at MTD (HR 6.4)